CN114145716A - Blue light protection human body efficacy quantitative evaluation method and application thereof - Google Patents

Blue light protection human body efficacy quantitative evaluation method and application thereof Download PDF

Info

Publication number
CN114145716A
CN114145716A CN202111484743.7A CN202111484743A CN114145716A CN 114145716 A CN114145716 A CN 114145716A CN 202111484743 A CN202111484743 A CN 202111484743A CN 114145716 A CN114145716 A CN 114145716A
Authority
CN
China
Prior art keywords
blue light
area
index
light protection
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111484743.7A
Other languages
Chinese (zh)
Other versions
CN114145716B (en
Inventor
马彦云
濮伟霖
张蕊
王久存
刘玮
谈益妹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202111484743.7A priority Critical patent/CN114145716B/en
Publication of CN114145716A publication Critical patent/CN114145716A/en
Application granted granted Critical
Publication of CN114145716B publication Critical patent/CN114145716B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/443—Evaluating skin constituents, e.g. elastin, melanin, water
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/11—Complex mathematical operations for solving equations, e.g. nonlinear equations, general mathematical optimization problems

Landscapes

  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Pure & Applied Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Operations Research (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Software Systems (AREA)
  • Databases & Information Systems (AREA)
  • Dermatology (AREA)
  • Algebra (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides a quantitative evaluation method for human body efficacy of blue light protection and application thereof. The method for quantitatively evaluating the human body efficacy of blue light protection comprises the following steps: setting a test area, a control area and a standard area on the skin to be tested, and measuring the melanin index, the brightness index and the skin yellow index of each area; coating a blue light protection sample in the test area; blue light irradiation is carried out on the test area and the control area, and the melanin index, the brightness index and the yellow dyeing index of the skin of the test area, the control area and the standard area are respectively measured; and calculating the blue light protection index. The invention provides a quantitative evaluation method for human body efficacy of blue light protection, which makes up the deficiency of the evaluation method for the blue light protection efficacy, provides a more intuitive evaluation method for blue light protection samples, and has important significance for research and development of the blue light protection samples.

Description

Blue light protection human body efficacy quantitative evaluation method and application thereof
Technical Field
The invention relates to the field of technical cosmetics and skin science, in particular to a quantitative evaluation method for human body efficacy of blue light protection and application thereof.
Background
Blue light is visible light generally existing in daily life, has the wavelength of 400-500nm, and belongs to high-energy visible light. The influence of blue light on human body is multifaceted, which can not only cause damage to human visual system, but also influence the biological rhythm of human body. Research shows that high-energy blue light can cause serious loss to human skin, can cause yellow spots and freckles, accelerate skin aging, cause skin allergy and influence sleep quality. Blue light irradiation can cause the skin of people with dark skin color to have obvious pigmentation, but has slight influence on people with light skin color, and particularly seriously influences the skin color of people in China. In modern society, electronic products are more and more abundant, but the blue light intensity of these electronic products is very large, such as computers, televisions, mobile phones, and so on.
At present, the market potential of a protection sample for blue light is huge, but an effective protection sample is lacked, and one important reason is that a blue light protection efficacy evaluation method is lacked. Therefore, the method for evaluating the human body efficacy of blue light protection based on the skin characteristics of Chinese people has great market potential.
Disclosure of Invention
The invention aims to provide a quantitative evaluation method for human body efficacy of blue light protection, and aims to solve the technical problem of the deficiency of the evaluation method for the blue light protection efficacy.
In order to realize the purpose, the invention provides a quantitative evaluation method for human body efficacy of blue light protection, which comprises the following steps:
step one, setting a test area, a contrast area and a standard area on skin to be tested, and measuring melanin index, brightness index and skin yellow index of each area;
coating a blue light protection sample in the test area;
thirdly, performing blue light irradiation on the test area and the control area, and respectively measuring the melanin index M, the brightness index L and the yellow dyeing index b of the skin of the test area, the control area and the standard area; repeating the blue light irradiation and the index measurement for multiple times according to the same time interval, and recording data;
step four, calculating the blue light protection index according to the data obtained in the step three, wherein the calculation formula comprises the following steps:
the method comprises the following steps:
Figure BDA0003397058010000021
or
The second formula:
Figure BDA0003397058010000022
wherein,
Figure BDA0003397058010000023
in the formula, BPF is a blue light protection index; ciAs a control area and a markA difference in skin melanin index of the quasi-region, or a difference in lightness index of the control region from the standard region, or a difference in ITA ° index of the control region from the standard region; ITA ° is used to characterize skin tone;
Figure BDA0003397058010000024
is CiThe mean value of (a); piThe difference value of the skin melanin indexes of the test area and the standard area, or the difference value of the brightness indexes of the test area and the standard area, or the difference value of the ITA DEG indexes of the test area and the standard area;
Figure BDA0003397058010000025
is PiThe mean value of (a); t isiFor the number of days of the test,
Figure BDA0003397058010000026
is TiThe mean value of (a); n is the number of days of the measured data, i is an integer of 1: n; k is a radical ofcontrolThe slope, k, of a line fitted to the skin color change value versus time for the control regionproductThe slope of the line fitted to the skin color change value and time for the test area.
Further, the calculation formula of ITA ° is:
Figure BDA0003397058010000027
l is the lightness index and b is the skin yellow index.
Further, the method comprises a fifth step, specifically: and repeating the first step to the fourth step, carrying out a plurality of parallel tests, calculating a mean value and a blue light protection index, and taking the blue light protection index calculated by the data mean value as a quantitative evaluation standard of the efficacy of blue light protection.
Further, the proportion of the wavelength of the light source irradiated by the blue light in a waveband of 400-700 nm is more than or equal to 50%.
Further, the proportion of the light source irradiated by the blue light in a wave band with the wavelength less than 400nm is less than or equal to 2.5 percent.
Further, the area of the test area is 4-20 cm2。
Further, the coating weight of the blue light protection sample in the test area is 2-5 mg/cm2。
Further, the test area is subjected to blue light irradiation after waiting for at least 15 minutes after the blue light protection sample is coated.
Further, the dose of blue light irradiation is less than or equal to the maximum blue light irradiation dose.
Further, the maximum blue irradiation dose is derived from: based on the lowest irradiation dose or the shortest irradiation time for which the skin appears dark spots, the maximum blue irradiation dose for normal skin is reduced by 1.25 times, expressed as MBD.
Further, in the third step, the time interval is 1 to 2 days.
Further, in the fourth step, n in the formula is 4-10.
Further, the skin to be detected is local skin of the detector.
Further, the examiner satisfies the following requirements:
(1) the number of testers is at least 30;
(2) selecting a person who is detected in a healthy volunteer of 18-60 years old, and selecting male and female;
(3) no history of the prior art without the photosensitive disease, and no medicine influencing the photosensitivity is used in 6 months before the test;
(4) according to Fitzpatrick skin typing, the skin type of a detected person is more than type III, wherein the types III and IV are not less than 5 persons;
(5) the skin of the tested part should have no pigmentation, inflammation, scar, pigmented nevus and hairy;
(6) pregnancy, lactation, oral or topical anti-inflammatory drugs, such as: corticosteroid hormones, or those who have received similar tests within the last month, should be excluded from testing.
The test area and the control area of the invention do not receive the blue light irradiation dose higher than the maximum blue light irradiation dose MBD.
The invention also provides application of the blue light protection human body efficacy quantitative evaluation method in blue light protection detection of cosmetics.
The invention has the beneficial effects that:
the invention provides a quantitative evaluation method for human body efficacy of blue light protection, which makes up the deficiency of the evaluation method for the blue light protection efficacy, provides a more intuitive evaluation method for blue light protection samples, and has important significance for research and development of the blue light protection samples.
Drawings
FIG. 1 is a line graph of Delta M on the Y axis and days on the X axis for example 1 of the present invention.
FIG. 2 is a line graph of Delta L on the Y axis and days on the X axis for example 1 of the present invention.
FIG. 3 is a line graph of example 1 of the present invention with Delta ITA ° on the Y-axis and days on the X-axis.
FIG. 4 is a line graph of Delta M on the Y-axis and days on the X-axis for example 2 of the present invention.
FIG. 5 is a line graph of Delta L on the Y axis and days on the X axis for example 2 of the present invention.
FIG. 6 is a line graph of Delta ITA ° on the Y axis and days on the X axis in example 2 of the present invention
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings of the present invention, and it is obvious that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. Unless defined otherwise, technical or scientific terms used herein shall have the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs. As used herein, the word "comprising" and similar words are intended to mean that the element or item listed before the word covers the element or item listed after the word and its equivalents, but does not exclude other elements or items.
The embodiment of the invention provides a blue light protection human body efficacy quantitative evaluation method, which comprises the following steps:
step one, setting a test area, a contrast area and a standard area on skin to be tested, and measuring melanin index, brightness index and skin yellow index of each area;
coating a blue light protection sample in the test area;
thirdly, performing blue light irradiation on the test area and the control area, and respectively measuring the melanin index M, the brightness index L and the yellow dyeing index b of the skin of the test area, the control area and the standard area; repeating the blue light irradiation and the index measurement for multiple times according to the same time interval, and recording data;
step four, calculating the blue light protection index according to the data obtained in the step three, wherein the calculation formula comprises the following steps:
the method comprises the following steps:
Figure BDA0003397058010000051
or
The second formula:
Figure BDA0003397058010000052
wherein,
Figure BDA0003397058010000053
in the formula, BPF is a blue light protection index; ciThe difference value of the skin color index of the contrast area and the skin color index of the standard area is the difference value of the skin melanin index M value of the contrast area and the M value of the standard area, or the difference value of the brightness index L value of the contrast area and the L value of the standard area, or the difference value of the ITA DEG index of the contrast area and the ITA DEG value of the standard area;
Figure BDA0003397058010000054
is CiThe mean value of (a); piThe difference value of the skin color index of the test area and the skin color index of the standard area, namely the difference value of the skin melanin index M value of the test area and the skin melanin index M value of the standard area, or the brightness index L value of the test area and the standard areaThe difference of the values of the domains L or the difference of the ITA DEG index of the test area and the ITA DEG value of the standard area; ITA ° is used to characterize skin tone;
Figure BDA0003397058010000055
is PiThe mean value of (a); t isiFor the number of days of the test,
Figure BDA0003397058010000056
is the mean value of Ti; n is the number of days of the measured data, i is an integer of 1: n; k is a radical ofcontrolThe slope, k, of a line fitted to the skin color change value versus time for the control regionproductThe slope of the line fitted to the skin color change value and time for the test area.
In detail, the test area, the control area and the standard area are adjacent, and the skin state is similar. The processing modes of the three methods are different: testing area, coating product and lighting; a control area, not coated with product, only illuminated; standard area: the uncoated product was not illuminated.
For example, the standard area can be selected from the part below the scapula when the examinee is in the prone position, the part is close to the test area and the control area, the skin is smooth, and the skin color texture is uniform.
During the research, the inventor finds that the document "Skin color type polarity and sunscreening pathways" reports ITA ° (inductive type Angle) for characterizing Skin color, and can accurately reflect the Skin color at the level of the Skin brightness index L value and the yellow dyeing index b value, and the larger the value, the brighter and whiter the Skin. The calculation formula for ITA ° is:
Figure BDA0003397058010000057
l is the lightness index and b is the skin yellow index. The present invention uses this ITA ° to characterize skin color.
In some embodiments, the method may further include a fifth step, specifically: and repeating the first step to the fourth step, carrying out a plurality of parallel tests, calculating a mean value and a blue light protection index, and taking the blue light protection index calculated by the data mean value as a quantitative evaluation standard of the efficacy of blue light protection.
In some embodiments, the proportion of the wavelength of the light source irradiated by the blue light in the 400-700 nm wave band is greater than or equal to 50%; for example, it may be 50%, 60%, 70%, 80%. The proportion of the light source irradiated by the blue light in a wave band with the wavelength less than 400nm is less than or equal to 2.5 percent; for example, it may be 2.5%, 2.0%, 1.5%, 1.0%.
In the examples, the test area coated sample had an area of not less than 4cm2The coating weight is 2mg/cm2And waiting for at least 15 minutes after the coating is uniform.
In some embodiments, the area of the test area is 4-20 cm2. In other words, the coating area of the blue light protection sample is 4-20 cm2. For example, the test area may have an area of 4cm2、5cm2、7cm2、10cm2、12cm2、15cm2、18cm2Or 20cm2。
In some embodiments, the test area is subjected to blue light irradiation after waiting at least 15 minutes after the blue light protection sample is applied.
In some embodiments, the coating amount of the blue light protection sample in the test area is 2-5 mg/cm2. Preferably, the coating weight of the blue-light protection sample in the test area is 2mg/cm2。
In some embodiments, the dose of blue light irradiation is less than or equal to the maximum blue light irradiation dose. Further, the maximum blue irradiation dose is derived from: based on the lowest irradiation dose or the shortest irradiation time for which the skin appears dark spots, the maximum blue irradiation dose for normal skin is reduced by 1.25 times, expressed as MBD.
In some embodiments, in step three, the time interval is 1-2 days; preferably, the time interval is 1 day. In the fourth step, n in the formula is 4-10; for example, n may be 4, 5, 6, 7, 8, 9, or 10.
The skin to be detected is the local skin of the detector.
For example, the maximum blue irradiation dose confirmation methodThe method can be as follows: selecting irradiation area on the skin of the back or abdomen of the examiner, and taking 6 spots at 50J/cm2、60J/cm2、75J/cm2、95J/cm2、120J/cm2、150J/cm2The blue lights are respectively irradiated, and observed 2 hours after irradiation; based on the lowest irradiation dose or the shortest irradiation time for which the skin appears dark spots, the maximum blue irradiation dose for normal skin is reduced by 1.25 times, expressed as MBD.
For example, the examiner should satisfy the following requirements:
(1) the number of testers is at least 30;
(2) selecting a person who is detected in a healthy volunteer of 18-60 years old, and selecting male and female;
(3) no history of the prior art without the photosensitive disease, and no medicine influencing the photosensitivity is used in 6 months before the test;
(4) according to Fitzpatrick skin typing, the skin type of a detected person is more than type III, wherein the types III and IV are not less than 5 persons;
(5) the skin of the tested part should have no pigmentation, inflammation, scar, pigmented nevus and hairy;
(6) pregnancy, lactation, oral or topical anti-inflammatory drugs, such as: corticosteroid hormones, or those who have received similar tests within the last month, should be excluded from testing.
In addition, the calculation formula of the blue light protection index is derived by the following method; calculating slope k by using least square method with time as X axis and difference between melanin index M, brightness index L or ITA DEG of control region and standard region as Y axiscontrol(ii) a In the same method, the time is taken as an X axis, the difference value between the melanin index M, the brightness index L or the ITA DEG of the test area and the standard area is taken as a Y axis, and the slope k is calculated by adopting a least square methodproduct；
Figure BDA0003397058010000071
Figure BDA0003397058010000072
Figure BDA0003397058010000073
Or,
Figure BDA0003397058010000081
Figure BDA0003397058010000082
Figure BDA0003397058010000083
wherein,
Figure BDA0003397058010000084
the invention is described in further detail with reference to a part of the test results, which are described in detail below with reference to specific examples.
Example 1
The embodiment provides a quantitative evaluation method for human body efficacy of blue light protection.
The blue light source is: the relative proportion of 400-700 nm is not less than 50%, and the wave band with the wavelength less than 400nm is not more than 2.5%.
Test sample (i.e. protective sample): sample 1 is a company product protective cream (from Shanghai Fissister detection technology Co., Ltd., a self-made sample).
The examiner satisfies the following requirements:
(1) the number of testers is 35;
(2) selecting a person who is detected in a healthy volunteer of 18-60 years old, and selecting male and female;
(3) no history of the prior art without the photosensitive disease, and no medicine influencing the photosensitivity is used in 6 months before the test;
(4) the skin type of the subject is more than type III, wherein the skin types III and IV are not less than 5 persons;
(5) the skin of the tested part should have no pigmentation, inflammation, scar, pigmented nevus and hairy;
(6) pregnancy, lactation, oral or topical anti-inflammatory drugs, such as: corticosteroid hormones, or those who have received similar tests within the last month, should be excluded from testing.
The blue light irradiation dose of a detector is confirmed before the detector receives blue light irradiation for 2 hours, and the specific operation is as follows;
determination of maximum blue light irradiation dose MBD: selecting irradiation area on the skin of the back of the subject, and taking 6 points at 50J/cm2、60J/cm2、75J/cm2、95J/cm2、120J/cm2、150J/cm2And observed 2 hours after irradiation. Based on the lowest irradiation dose or the shortest irradiation time of the skin with black spots, the maximum blue light irradiation dose of the normal skin of the examinee is reduced by 1.25 times and is expressed by MBD. The test area and the control area do not receive the blue light irradiation amount higher than the maximum blue light irradiation dose MBD.
The method for quantitatively evaluating the human body efficacy of blue light protection comprises the following steps of testing each detector according to the following method:
step 1, marking the area of the back of a detector in advance to be not less than 4cm2The test area, the control area and the standard area corresponding to the test area, and determining the melanin index M, the brightness index L and the skin yellow index b of each area;
step 2. coating the sample in the test area with a coating weight of 2mg/cm2Uniformly coating the mixture by using a latex finger stall and waiting for 15 minutes;
step 3, irradiating the test area and the control area by using blue light, and measuring the melanin index M, the brightness index L and the yellow dyeing index b of the skin of the test area, the control area and the standard area; repeating the irradiation and index measurement for multiple times at 1 day intervals, and recording 5 groups of data;
step 4, calculating the blue light protection index by the following formula;
Figure BDA0003397058010000091
or:
Figure BDA0003397058010000092
wherein,
Figure BDA0003397058010000093
BPF in the above formula is the blue light protection index, CiIs the difference value of skin melanin index M, brightness index L or ITA DEG of the control area and skin melanin index M, brightness index L or ITA DEG of the standard area, ITA DEG can be calculated by L and b,
Figure BDA0003397058010000104
is CiThe mean value of (a); piThe difference between the melanin index M, the lightness index L or ITA DEG of the skin in the test area and the melanin index M, the lightness index L or ITA DEG of the skin in the standard area,
Figure BDA0003397058010000105
is PiThe mean value of (a); t isiFor the number of days of the test,
Figure BDA0003397058010000106
is TiThe mean value of (a); n is the number of days of measurement data, and i is an integer of 1 to n.
ITA ° is calculated by the following formula:
Figure BDA0003397058010000101
ITA ° can accurately reflect the skin color at the level of the L value and b value, and the larger the value, the brighter the skin.
Step 5, repeating the steps for parallel tests, and calculating the blue light protection indexAverage of blue light protection index in multiple parallel tests
Figure BDA0003397058010000102
The method is used as a quantitative evaluation standard of the human body efficacy of blue light protection.
Please refer to fig. 1 to 3 for the measurement results of skin melanin index M, lightness index L, and skin color index ITA ° in the present embodiment; in the figure, control refers to the control area (uncoated sample group), product refers to the test area (coated sample group), day is the number of days. FIG. 1 is a line graph with Delta M (i.e., the amount of change in melanin index M) as the Y-axis and days as the X-axis. FIG. 2 is a line graph with Delta L (i.e., the amount of change in the luminance index L) as the Y-axis and days as the X-axis. FIG. 3 is a line graph with Delta ITA (i.e., the amount of change in ITA) on the Y-axis and days on the X-axis.
Example 2
In this example, the examiner was tested by the method of example 1, and the obtained data are shown in table 1.
The detector is: data number F024, gender: male; age: age 58; skin type: and III.
Table 1: distribution of Delta M values at 5 time points for tester F024 in uncoated versus coated sample groups
Figure BDA0003397058010000103
Figure BDA0003397058010000111
In table 1, M is the melanin index; delta M is the M difference between the test area and the standard area or between the control area and the standard area, and represents the variation of the melanin index M.
Plotting Delta M as Y axis and days as X axis, as shown in FIG. 1, and calculating the slope by the calculation formula of example 1, the slope K1 of the control area, i.e., the group of non-smeared samples, was 2.18; the slope of the test area, i.e., the smear sample set, was 2.01 at K2. The BPF was calculated to be 2.18/2.01 to 1.09, see fig. 4.
Table 2: distribution of Delta L values at 5 time points for tester F024 in uncoated versus coated sample groups
Figure BDA0003397058010000112
In table 2, L is the luminance index; delta L is the L difference between the test area and the standard area or the L difference between the control area and the standard area, and represents the variation of L.
Plotting Delta L as Y axis and days as X axis, as shown in FIG. 2, and calculating the slope by the calculation formula of example 1 to obtain a slope K2 of-2.12 for the control area, i.e., the group of non-smeared samples; the slope K2 for the test area, i.e., the smear sample set, was-1.93. BPF-2.12/-1.93-1.10, see fig. 5.
Table 3: distribution of Delta ITA values at 5 time points for tester F024 in the uncoated and coated sample groups
Figure BDA0003397058010000113
Figure BDA0003397058010000121
In table 3, ITA ° is skin color index; delta ITA ° is the difference in ITA ° between the test and standard regions or the difference in ITA ° between the control and standard regions, indicating the amount of change in ITA °.
Plotting Delta ITA ° as Y axis and days as X axis, as shown in FIG. 3, and calculating the slope by the calculation formula of example 1, the slope K1 of the control area, i.e., the non-smeared sample group, was-3.88; the slope K2 for the test area, i.e., the smear sample set, was-3.73. BPF-3.88/-3.73-1.04, see fig. 6.
Summarizing the results of the three groups of data to obtain:
table 4: slope (K) and BPF of subject F024 at 5 time points in sample and uncoated sample groups
K Sample set Uncoated sample set BPF
Delta M 2.01 2.18 1.09
Delta L -1.93 -2.12 1.10
Delta ITA° -3.73 -3.88 1.04
Example 3
For sample 1 in example 1, 35 subjects (F001 to F036, where F027 data was missing) were tested, the data are shown in table 5, a statistical description of the delta values per day for the product group versus the control group, and table 5 includes table 5.1, table 5.2, and table 5.3.
TABLE 5.1
Figure BDA0003397058010000122
Figure BDA0003397058010000131
TABLE 5.2
Figure BDA0003397058010000132
TABLE 5.3
Figure BDA0003397058010000133
Figure BDA0003397058010000141
The mean values from the data in table 5 were fitted to a linear equation over time to calculate the slope and BPF, and the results are shown in table 6, table 6 for the slope and BPF at delta M, delta L and delta ITA ° levels for the product and control groups.
TABLE 6
K Product Control BPF
Delta M 0.63 1.12 1.77
Delta L -0.67 -1.19 1.77
Delta ITA° -1.77 -2.43 1.37
In conclusion, the method can effectively detect the blue light protection index of the protection sample, provides a more intuitive evaluation method for the blue light protection sample, and has important significance for the research and development of the blue light protection sample.
Although the embodiments of the present invention have been described in detail hereinabove, it is apparent to those skilled in the art that various modifications and variations can be made to these embodiments. However, it is to be understood that such modifications and variations are within the scope and spirit of the present invention as set forth in the following claims. Moreover, the invention as described herein is capable of other embodiments and of being practiced or of being carried out in various ways.

Claims (10)

1. A blue light protection human body efficacy quantitative evaluation method is characterized by comprising the following steps:
step one, setting a test area, a contrast area and a standard area on skin to be tested, and measuring melanin index, brightness index and skin yellow index of each area;
coating a blue light protection sample in the test area;
thirdly, performing blue light irradiation on the test area and the control area, and respectively measuring the melanin index, the brightness index and the yellow dyeing index of the skin of the test area, the control area and the standard area; repeating the blue light irradiation and the index measurement for multiple times according to the same time interval, and recording data;
step four, calculating the blue light protection index according to the data obtained in the step three, wherein the calculation formula comprises the following steps:
the method comprises the following steps:
Figure FDA0003397057000000011
or
The second formula:
Figure FDA0003397057000000012
wherein,
Figure FDA0003397057000000013
in the formula, BPF is a blue light protection index; ciThe difference of the skin melanin indexes of the control area and the standard area, or the difference of the brightness indexes of the control area and the standard area, or the difference of the ITA DEG indexes of the control area and the standard area; ITA ° is used to characterize skin tone;
Figure FDA0003397057000000014
is CiThe mean value of (a); piThe difference value of the skin melanin indexes of the test area and the standard area, or the difference value of the brightness indexes of the test area and the standard area, or the difference value of the ITA DEG indexes of the test area and the standard area;
Figure FDA0003397057000000015
is PiThe mean value of (a); t isiFor the number of days of the test,
Figure FDA0003397057000000016
is TiThe mean value of (a); n is the number of days of the measured data, i is an integer from 1 to n; k is a radical ofcontrolThe slope, k, of a line fitted to the skin color change value versus time for the control regionproductFitting the slope of a straight line for the skin color change value and the time of the test area;
the calculation formula for ITA ° is:
Figure FDA0003397057000000017
l is the lightness index and b is the skin yellow index.
2. The method for quantitatively evaluating the human body efficacy of blue light protection according to claim 1, wherein the method comprises a fifth step, specifically: and repeating the first step to the fourth step, carrying out a plurality of parallel tests, calculating a mean value and a blue light protection index, and taking the blue light protection index calculated by the data mean value as a quantitative evaluation standard of the efficacy of blue light protection.
3. The method for quantitatively evaluating the human body efficacy of blue light protection according to claim 1, wherein the ratio of the wavelength of the light source irradiated by the blue light in the waveband of 400-700 nm is greater than or equal to 50%; the proportion of the light source irradiated by the blue light in a wave band with the wavelength less than 400nm is less than or equal to 2.5 percent.
4. The method for quantitatively evaluating the human body efficacy of blue light protection according to claim 1, wherein the area of the test area is 4-20 cm2。
5. The method for quantitatively evaluating the human body efficacy of blue light protection according to claim 4, wherein the coating weight of the blue light protection sample is 2-5 mg/cm2。
6. The method for quantitatively evaluating the human body efficacy of blue light protection according to any one of claims 1 to 5, wherein after the blue light protection sample is coated, blue light irradiation is performed after waiting at least 15 minutes.
7. The method for quantitatively evaluating the human body efficacy of blue light protection according to claim 1, wherein the dose of blue light irradiation is less than or equal to the maximum dose of blue light irradiation;
preferably, the maximum blue irradiation dose is derived from: the maximum blue light irradiation dose of normal skin is reduced by 1.25 times based on the minimum irradiation dose or the minimum irradiation time of the skin with black spots.
8. The method for quantitatively evaluating the human body efficacy of blue light protection according to claim 1, wherein the time interval is 1 to 2 days in step three.
9. The method for quantitatively evaluating the human body efficacy of blue light protection according to claim 1, wherein n in the formula is 4-10 in the fourth step.
10. The application of the blue-light protection human body efficacy quantitative evaluation method according to any one of claims 1-9 in blue-light protection detection of cosmetics.
CN202111484743.7A 2021-12-07 2021-12-07 Human body efficacy quantitative evaluation method for blue light protection and application thereof Active CN114145716B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111484743.7A CN114145716B (en) 2021-12-07 2021-12-07 Human body efficacy quantitative evaluation method for blue light protection and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111484743.7A CN114145716B (en) 2021-12-07 2021-12-07 Human body efficacy quantitative evaluation method for blue light protection and application thereof

Publications (2)

Publication Number Publication Date
CN114145716A true CN114145716A (en) 2022-03-08
CN114145716B CN114145716B (en) 2024-02-09

Family

ID=80453288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111484743.7A Active CN114145716B (en) 2021-12-07 2021-12-07 Human body efficacy quantitative evaluation method for blue light protection and application thereof

Country Status (1)

Country Link
CN (1) CN114145716B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100145886A1 (en) * 2008-12-08 2010-06-10 Conopco, Inc., D/B/A Unilever Evaluation and Selection Process for Consumer Products
CN111787847A (en) * 2018-02-26 2020-10-16 株式会社爱茉莉太平洋 Skin change measuring device and method using blue light, and blue light irradiation device
KR20210091480A (en) * 2020-01-14 2021-07-22 (주)지에프씨생명과학 Assessment method of protection efficacy of blue light in cosmetics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100145886A1 (en) * 2008-12-08 2010-06-10 Conopco, Inc., D/B/A Unilever Evaluation and Selection Process for Consumer Products
CN111787847A (en) * 2018-02-26 2020-10-16 株式会社爱茉莉太平洋 Skin change measuring device and method using blue light, and blue light irradiation device
KR20210091480A (en) * 2020-01-14 2021-07-22 (주)지에프씨생명과학 Assessment method of protection efficacy of blue light in cosmetics

Also Published As

Publication number Publication date
CN114145716B (en) 2024-02-09

Similar Documents

Publication Publication Date Title
Papazoglou et al. Image analysis of chronic wounds for determining the surface area
Koga et al. Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia
Newton-Bishop et al. Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate
US5671735A (en) Method and apparatus for detecting and measuring conditions affecting color
Kvaskoff et al. Solar elastosis and cutaneous melanoma: a site‐specific analysis
McLean et al. “Sunburn” freckles, café-au-lait macules, and other pigmented lesions of schoolchildren: The Vancouver Mole Study
Lock‐Andersen et al. Threshold level for measurement of UV sensitivity: reproducibility of phototest
McCreath et al. Use of Munsell color charts to measure skin tone objectively in nursing home residents at risk for pressure ulcer development
Kikuchi et al. Image analysis of skin color heterogeneity focusing on skin chromophores and the age‐related changes in facial skin
Hallam et al. A practical and objective approach to scar colour assessment
Pugazhenthi et al. Skin disease detection and classification
Rubegni et al. Melanocytic skin lesions and pregnancy: digital dermoscopy analysis
Chen et al. Colour analysis of skin lesion regions for melanoma discrimination in clinical images
Bakos et al. A melanoma risk score in a Brazilian population
CN1191016A (en) Method and apparatus for detecting and measuring conditions affecting color
Seo et al. GWAS identifies multiple genetic loci for skin color in Korean women
Scafide et al. Reliability of tristimulus colourimetry in the assessment of cutaneous bruise colour
Chang et al. A systematic heuristic approach for feature selection for melanoma discrimination using clinical images
CN114145716A (en) Blue light protection human body efficacy quantitative evaluation method and application thereof
Yajima et al. Spectrophotometric and tristimulus analysis of the colors of subcutaneous bleeding in living persons
Mesli et al. Determination of the age of bruises using a bilirubinometer
CN106846422A (en) The recognition methods of antitan agent situation
Nishino et al. Detection and visualization of intracutaneous allergic type‐specific elements using long‐wavelength near‐infrared hyperspectral imaging
CN115824892A (en) Method for testing waterproof performance of color cosmetics product
Glazer et al. Quantitative ABCD parameters measured by a multispectral digital skin lesion analysis device for evaluation of suspicious pigmented skin lesions strongly correlate with clinical ABCD observations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant